{"hands_on_practices": [{"introduction": "The ability of *Candida albicans* to switch between a budding yeast and an invasive hyphal form is a hallmark of its pathogenicity. This exercise moves beyond a qualitative description to a quantitative analysis of this change. By modeling the two forms with simple geometry, we can calculate the change in the surface area-to-volume ratio, a fundamental physical property that has profound consequences for nutrient absorption and interaction with the host immune system. [@problem_id:4616027]", "problem": "Candida albicans undergoes morphogenetic switching between a yeast form and a hyphal form. For a single yeast cell, approximate its geometry as a sphere of radius $r_{y} = 2.5\\,\\mu\\mathrm{m}$. For a single hyphal segment emerging from a mother cell, approximate its geometry as a right circular cylinder of radius $r_{h} = 1.0\\,\\mu\\mathrm{m}$ and length $L = 20\\,\\mu\\mathrm{m}$, capped distally by a hemisphere of the same radius. Assume the proximal base of the cylinder is attached to the mother cell and therefore does not contribute exposed end-cap surface area. Using standard geometric measures, determine the surface area-to-volume ratio $\\mathrm{SA}/V$ for each morphology and then compute the fold-change in $\\mathrm{SA}/V$ defined as\n$$F = \\frac{(\\mathrm{SA}/V)_{\\text{hypha}}}{(\\mathrm{SA}/V)_{\\text{yeast}}}.$$\nTreat the hyphal and yeast forms as having homogeneous cell wall transporter density per unit area and comparable metabolic demand per unit volume. Based on first principles, briefly justify how the calculated change in $\\mathrm{SA}/V$ would be expected to affect nutrient influx and host Pattern Recognition Receptor (PRR) engagement with exposed Pathogen-Associated Molecular Patterns (PAMPs). Use micrometers for all geometric quantities. Express the final numerical value of $F$ as a dimensionless decimal rounded to four significant figures.", "solution": "The problem is to determine the fold-change in the surface area-to-volume ratio ($\\mathrm{SA}/V$) when a *Candida albicans* cell switches from a yeast morphology to a hyphal morphology, based on simplified geometric models, and to provide a biophysical justification for the consequences of this change.\n\nFirst, we analyze the yeast form, approximated as a sphere of radius $r_{y}$.\nThe surface area of a sphere is given by the formula:\n$$ \\mathrm{SA}_{\\text{yeast}} = 4\\pi r_{y}^{2} $$\nThe volume of a sphere is given by:\n$$ V_{\\text{yeast}} = \\frac{4}{3}\\pi r_{y}^{3} $$\nThe surface area-to-volume ratio for the yeast form is therefore:\n$$ (\\mathrm{SA}/V)_{\\text{yeast}} = \\frac{4\\pi r_{y}^{2}}{\\frac{4}{3}\\pi r_{y}^{3}} = \\frac{3}{r_{y}} $$\nGiven the yeast radius $r_{y} = 2.5\\,\\mu\\mathrm{m}$, the numerical value of this ratio is:\n$$ (\\mathrm{SA}/V)_{\\text{yeast}} = \\frac{3}{2.5\\,\\mu\\mathrm{m}} = 1.2\\,(\\mu\\mathrm{m})^{-1} $$\n\nNext, we analyze the hyphal form. It is approximated as a composite structure consisting of a right circular cylinder of radius $r_{h}$ and length $L$, attached proximally to the mother cell, and capped distally by a hemisphere of the same radius $r_{h}$.\nThe total exposed surface area of the hypha, $\\mathrm{SA}_{\\text{hypha}}$, is the sum of the lateral surface area of the cylinder and the surface area of the distal hemispherical cap. The proximal circular base is stated to be unexposed and does not contribute.\nThe lateral surface area of the cylinder is $2\\pi r_{h} L$.\nThe surface area of the hemispherical cap is $\\frac{1}{2}(4\\pi r_{h}^{2}) = 2\\pi r_{h}^{2}$.\nThus, the total surface area of the hyphal form is:\n$$ \\mathrm{SA}_{\\text{hypha}} = 2\\pi r_{h} L + 2\\pi r_{h}^{2} = 2\\pi r_{h} (L + r_{h}) $$\nThe total volume of the hypha, $V_{\\text{hypha}}$, is the sum of the volume of the cylinder and the volume of the hemisphere.\nThe volume of the cylinder is $\\pi r_{h}^{2} L$.\nThe volume of the hemisphere is $\\frac{1}{2}(\\frac{4}{3}\\pi r_{h}^{3}) = \\frac{2}{3}\\pi r_{h}^{3}$.\nThus, the total volume of the hyphal form is:\n$$ V_{\\text{hypha}} = \\pi r_{h}^{2} L + \\frac{2}{3}\\pi r_{h}^{3} = \\pi r_{h}^{2} (L + \\frac{2}{3}r_{h}) $$\nThe surface area-to-volume ratio for the hyphal form is:\n$$ (\\mathrm{SA}/V)_{\\text{hypha}} = \\frac{2\\pi r_{h} (L + r_{h})}{\\pi r_{h}^{2} (L + \\frac{2}{3}r_{h})} = \\frac{2(L + r_{h})}{r_{h}(L + \\frac{2}{3}r_{h})} $$\nGiven the hyphal radius $r_{h} = 1.0\\,\\mu\\mathrm{m}$ and length $L = 20\\,\\mu\\mathrm{m}$, the numerical value of this ratio is:\n$$ (\\mathrm{SA}/V)_{\\text{hypha}} = \\frac{2(20\\,\\mu\\mathrm{m} + 1.0\\,\\mu\\mathrm{m})}{(1.0\\,\\mu\\mathrm{m})(20\\,\\mu\\mathrm{m} + \\frac{2}{3}(1.0\\,\\mu\\mathrm{m}))} = \\frac{2(21)}{20 + \\frac{2}{3}}\\,(\\mu\\mathrm{m})^{-1} = \\frac{42}{\\frac{62}{3}}\\,(\\mu\\mathrm{m})^{-1} = \\frac{126}{62}\\,(\\mu\\mathrm{m})^{-1} = \\frac{63}{31}\\,(\\mu\\mathrm{m})^{-1} \\approx 2.0323\\,(\\mu\\mathrm{m})^{-1} $$\n\nThe fold-change, $F$, is the ratio of the hyphal $\\mathrm{SA}/V$ to the yeast $\\mathrm{SA}/V$.\n$$ F = \\frac{(\\mathrm{SA}/V)_{\\text{hypha}}}{(\\mathrm{SA}/V)_{\\text{yeast}}} = \\frac{\\frac{2(L + r_{h})}{r_{h}(L + \\frac{2}{3}r_{h})}}{\\frac{3}{r_y}} = \\frac{2 r_{y} (L + r_{h})}{3 r_{h} (L + \\frac{2}{3}r_{h})} $$\nSubstituting the given numerical values:\n$$ F = \\frac{2 (2.5) (20 + 1.0)}{3 (1.0) (20 + \\frac{2}{3}(1.0))} = \\frac{5 \\times 21}{3 \\times (20 + \\frac{2}{3})} = \\frac{105}{3 \\times \\frac{62}{3}} = \\frac{105}{62} $$\nThe numerical value is $F \\approx 1.693548...$. Rounding to four significant figures, we get $F = 1.694$.\n\nThe result $F > 1$ indicates that the hyphal morphology has a significantly higher surface area-to-volume ratio than the yeast morphology. This has two primary biophysical consequences as requested:\n\n1.  **Nutrient Influx:** Assuming metabolic demand scales with cell volume and nutrient uptake scales with surface area (due to a homogeneous density of transporters), the $\\mathrm{SA}/V$ ratio is a direct measure of the cell's capacity for nutrient acquisition relative to its metabolic needs. A higher $\\mathrm{SA}/V$ ratio, as seen in the hyphal form, facilitates more efficient absorption of nutrients from the environment per unit of cellular machinery. This is a critical advantage for invasive growth, enabling the fungus to penetrate and colonize tissues where nutrients may be limited.\n\n2.  **Host PRR Engagement:** The surface of the pathogen is decorated with Pathogen-Associated Molecular Patterns (PAMPs), such as $\\beta$-glucans and mannans in the case of *C. albicans*. These PAMPs are recognized by Pattern Recognition Receptors (PRRs) on host immune cells. The total extent of interaction is proportional to the exposed surface area. The higher $\\mathrm{SA}/V$ ratio of the hyphal form means that, for a given cellular volume, a greater proportion of the organism's substance is presented at the host-pathogen interface. This leads to an amplified engagement with host PRRs, which can trigger a more potent or qualitatively different immune response compared to the more compact yeast form. The elongated shape of hyphae also fundamentally alters the nature of the physical interaction with immune cells, notably by frustrating phagocytosis.", "answer": "$$\\boxed{1.694}$$", "id": "4616027"}, {"introduction": "The transition to the hyphal form is not just a change in shape; it involves expressing specific genes that act as the pathogen's toolkit for invasion. This practice puts you in the role of a microbial geneticist, challenging you to predict the phenotypic consequences of deleting a single, crucial virulence gene, *ALS3*. This conceptual exercise demonstrates how to connect a specific genotype to its effect on virulence, a core skill in studying pathogenesis. [@problem_id:4616012]", "problem": "A hypha-competent strain of *Candida albicans* (wild type) and an otherwise isogenic strain carrying a loss-of-function mutation in the agglutinin-like sequence 3 gene (*ALS3*) are evaluated in a standardized murine oropharyngeal candidiasis model and in matched in vitro assays. The following outcome metrics are collected under conditions that robustly induce hyphal growth in both strains: epithelial invasion fraction $I$ (fraction of epithelial cells containing internalized hyphae after $90$ minutes), biofilm biomass $B$ (dry mass in $\\mathrm{mg}$ on silicone after $24$ hours), mucosal fungal burden $F$ (Colony-Forming Units (CFU) per gram of tongue tissue at $48$ hours), and mean survival time $T_s$ of infected animals. Baseline wild-type means are $I_{\\mathrm{WT}} = 0.38$, $B_{\\mathrm{WT}} = 12\\,\\mathrm{mg}$, $F_{\\mathrm{WT}} = 8\\times 10^5\\,\\mathrm{CFU/g}$, and $T_{s,\\mathrm{WT}} = 5\\,\\mathrm{days}$. \n\nUse the following fundamental base to reason about the expected phenotypes: \n- In microbial pathogenesis, adhesion to host tissues is a prerequisite for colonization and precedes invasion; invasion of epithelial cells by Candida albicans hyphae commonly occurs via host receptor-mediated endocytosis, triggered by hyphal surface invasins that bind epithelial receptors. \n- Biofilm formation requires an initial adhesive phase followed by maturation; the presence of hyphal adhesins facilitates both attachment to biotic and abiotic surfaces and intercellular cohesion.\n- Virulence in mucosal candidiasis correlates with effective adhesion, invasion, biofilm establishment, and tissue damage; reductions in these processes generally lower tissue fungal burden and prolong host survival, all else equal.\n- The *ALS3* gene product is a hyphal-associated adhesin/invasin that binds host epithelial receptors to promote adhesion and endocytosis; loss of *ALS3* does not abolish hyphal morphogenesis under hypha-inducing conditions but reduces receptor-mediated invasion and early biofilm formation. Redundancy with other adhesins (for example, agglutinin-like sequence 1 (*ALS1*) and hyphal wall protein 1 (*HWP1*)) can attenuate, but typically does not eliminate, the phenotype. \n\nWhich option best predicts the phenotypic consequences of an *ALS3* loss-of-function under these standardized conditions?\n\nA. $I$ decreases substantially (for example to $0.10$–$0.20$), $B$ decreases notably (for example to $6$–$9\\,\\mathrm{mg}$), $F$ decreases (for example by $\\approx 0.5$–$1$ $\\log_{10}$), and $T_s$ increases (for example to $7$–$9\\,\\mathrm{days}$), with hyphal morphogenesis preserved.\n\nB. No meaningful changes in $I$, $B$, $F$, or $T_s$ relative to wild type, because adhesin redundancy completely compensates for *ALS3* loss.\n\nC. $I$ and $B$ increase due to compensatory hyper-hyphal growth, leading to higher $F$ (for example $>10^6\\,\\mathrm{CFU/g}$) and shorter $T_s$ (for example $<4\\,\\mathrm{days}$).\n\nD. $I$ decreases, but $B$ increases due to a shift toward yeast-phase growth; $F$ and $T_s$ remain near wild-type values because secreted hydrolytic enzymes, not adhesins, determine virulence.", "solution": "The problem describes a controlled experiment comparing a wild-type *Candida albicans* strain to an isogenic mutant lacking the *ALS3* gene. The problem provides a set of principles governing *C. albicans* pathogenesis and asks for the expected phenotypic outcomes for the *ALS3* mutant.\n\n**Derivation of Expected Phenotypes**\n\nWe will analyze the expected changes for each metric based on the provided principles for the *ALS3* mutant strain compared to the wild-type.\n\n1.  **Epithelial Invasion Fraction ($I$)**: Principle $4$ states that the *ALS3* gene product is an invasin that binds host epithelial receptors to promote endocytosis, and its loss \"reduces receptor-mediated invasion\". Principle $1$ links invasion to invasins. Therefore, a loss-of-function mutation in *ALS3* must lead to a decrease in the epithelial invasion fraction $I$. The principle of redundancy (\"attenuate, but typically does not eliminate, the phenotype\") implies the decrease will be significant but not total. A reduction from $I_{\\mathrm{WT}} = 0.38$ to a lower value is expected.\n\n2.  **Biofilm Biomass ($B$)**: Principle $4$ states that *ALS3* is an adhesin and its loss \"reduces... early biofilm formation\". Principle $2$ states that biofilm formation requires adhesion. Thus, the loss of a major adhesin will impair the ability of the fungus to form a robust biofilm. This will result in a decrease in the biofilm biomass $B$ compared to the wild-type value of $B_{\\mathrm{WT}} = 12\\,\\mathrm{mg}$.\n\n3.  **Mucosal Fungal Burden ($F$) and Mean Survival Time ($T_s$)**: Principle $3$ establishes a direct correlation between virulence and the processes of adhesion, invasion, and biofilm formation. It further states that \"reductions in these processes generally lower tissue fungal burden and prolong host survival\". Since we have deduced that the *ALS3* mutant will have reduced invasion ($I$) and reduced biofilm formation ($B$), its overall virulence will be attenuated. This attenuated virulence will manifest as a lower mucosal fungal burden $F$ (a decrease from $F_{\\mathrm{WT}} = 8\\times 10^5\\,\\mathrm{CFU/g}$) and an increased mean survival time $T_s$ for the host animals (an increase from $T_{s,\\mathrm{WT}} = 5\\,\\mathrm{days}$).\n\n4.  **Hyphal Morphogenesis**: A critical piece of information from Principle $4$ is that \"loss of *ALS3* does not abolish hyphal morphogenesis under hypha-inducing conditions\". This means the mutant strain is still capable of forming hyphae, but the hyphae it forms are functionally deficient in adhesion and invasion mediated by the Als3 protein.\n\n**Summary of Predictions for the *ALS3* mutant:**\n-   $I$ decreases substantially.\n-   $B$ decreases notably.\n-   $F$ decreases.\n-   $T_s$ increases.\n-   Hyphal morphogenesis is preserved.\n\n**Evaluation of Options**\n\nNow we evaluate each option against these predictions.\n\n**A. $I$ decreases substantially (for example to $0.10$–$0.20$), $B$ decreases notably (for example to $6$–$9\\,\\mathrm{mg}$), $F$ decreases (for example by $\\approx 0.5$–$1$ $\\log_{10}$), and $T_s$ increases (for example to $7$–$9\\,\\mathrm{days}$), with hyphal morphogenesis preserved.**\n-   This option aligns perfectly with all our derived predictions. The decrease in $I$, $B$, and $F$, the increase in $T_s$, and the preservation of hyphal growth are all consistent with the loss of a key adhesin/invasin as described by the provided principles. The numerical examples are reasonable representations of an attenuated but not null phenotype.\n-   **Verdict: Correct.**\n\n**B. No meaningful changes in $I$, $B$, $F$, or $T_s$ relative to wild type, because adhesin redundancy completely compensates for *ALS3* loss.**\n-   This option claims complete compensation by redundancy. This directly contradicts Principle $4$, which states that redundancy \"can attenuate, but typically does not eliminate, the phenotype\". Therefore, meaningful changes are expected.\n-   **Verdict: Incorrect.**\n\n**C. $I$ and $B$ increase due to compensatory hyper-hyphal growth, leading to higher $F$ (for example $>10^6\\,\\mathrm{CFU/g}$) and shorter $T_s$ (for example $<4\\,\\mathrm{days}$).\"**\n-   This option predicts a gain of function and increased virulence from a loss-of-function mutation, which is biologically illogical in this context. It also posits \"compensatory hyper-hyphal growth,\" which contradicts the given information that hyphal morphogenesis is preserved, not enhanced. All resulting predictions (increased $F$, decreased $T_s$) are the opposite of what is expected.\n-   **Verdict: Incorrect.**\n\n**D. $I$ decreases, but $B$ increases due to a shift toward yeast-phase growth; $F$ and $T_s$ remain near wild-type values because secreted hydrolytic enzymes, not adhesins, determine virulence.**\n-   This option contains multiple falsehoods.\n    1.  It claims $B$ increases, which is contrary to the role of *ALS3* as an adhesin crucial for biofilm formation.\n    2.  It claims a \"shift toward yeast-phase growth,\" which is explicitly contradicted by the problem statement that hyphal morphogenesis is preserved under the given conditions.\n    3.  It claims $F$ and $T_s$ remain near wild-type levels, which ignores the direct contribution of adhesion/invasion to virulence as stated in Principle $3$.\n    4.  It presents a false dichotomy, suggesting only secreted enzymes determine virulence, which negates the established role of adhesins like the Als3 protein.\n-   **Verdict: Incorrect.**\n\nBased on the systematic application of the provided principles, Option A is the only one that presents a logically consistent and biologically sound set of phenotypic consequences for an *ALS3* loss-of-function mutation.", "answer": "$$\\boxed{A}$$", "id": "4616012"}, {"introduction": "Our ability to treat candidiasis is increasingly threatened by the emergence of drug resistance. This final practice delves into the molecular mechanisms of fluconazole resistance, a major clinical problem. Using a hypothetical scenario based on real-world data, you will model the combined impact of two distinct resistance mechanisms to predict the resulting increase in the drug's Minimum Inhibitory Concentration ($MIC$), reinforcing how molecular changes directly impact clinical outcomes. [@problem_id:4616017]", "problem": "A clinical isolate of *Candida albicans* exhibits both a point mutation in the lanosterol 14$\\alpha$-demethylase gene (*ERG11*), specifically a tyrosine-to-phenylalanine substitution at position $132$ (Y132F), and overexpression of the Adenosine Triphosphate (ATP)-Binding Cassette (ABC) efflux transporters *Candida* Drug Resistance $1$ and $2$ (*CDR1* and *CDR2*). The minimum inhibitory concentration (MIC) is the minimal extracellular drug concentration that reduces the net growth rate to non-positive values, which can be interpreted as the concentration required to achieve a sufficiently low intracellular fungal ergosterol synthesis so that population growth is halted. The antifungal fluconazole inhibits ERG11; mutations in ERG11 can reduce binding affinity, while efflux pump overexpression reduces intracellular drug concentration. Both mechanisms are well-established in medical microbiology as contributors to increased fluconazole MIC.\n\nYou are provided literature-calibrated fold changes in fluconazole MIC for each mechanism, reported across independent studies with sample sizes reflecting the number of isolates tested:\n\n- *ERG11* Y132F studies: fold increases $f_{T,1} = 8.0$ with $n_{T,1} = 30$, $f_{T,2} = 6.5$ with $n_{T,2} = 20$, and $f_{T,3} = 9.5$ with $n_{T,3} = 25$.\n- *CDR1*/*CDR2* overexpression studies: fold increases $f_{E,1} = 3.0$ with $n_{E,1} = 40$, $f_{E,2} = 4.0$ with $n_{E,2} = 35$, and $f_{E,3} = 2.5$ with $n_{E,3} = 25$.\n\nStarting from core pharmacological definitions and mechanisms of action, determine whether the combined impact on fluconazole MIC should be modeled additively or multiplicatively, and then calibrate each mechanism’s effect size using the sample-size-weighted geometric mean of the reported fold increases. Under the justified model, compute the predicted overall fold increase in fluconazole MIC for the isolate harboring both *ERG11* Y132F and *CDR1*/*CDR2* overexpression. Round your final answer to three significant figures. Express the final result as a dimensionless fold-change (no units).", "solution": "The problem asks to predict the combined effect of two drug resistance mechanisms on the fluconazole MIC. The solution is developed in three stages: justifying the interaction model, calibrating the individual effect sizes, and computing the overall effect.\n\n**1. Justification of the Interaction Model (Multiplicative vs. Additive)**\n\nThe two resistance mechanisms act at different points in the drug's mechanism of action. Let $C_{out}$ be the external drug concentration, and $C_{in}$ be the intracellular drug concentration. The Minimum Inhibitory Concentration (MIC) is the specific external concentration, $C_{out} = \\text{MIC}$, that results in a sufficient level of target inhibition to halt net population growth.\n\nFor a wild-type (susceptible) strain, let the MIC be $\\text{MIC}_{WT}$. This external concentration achieves a critical intracellular concentration, $C_{in,crit}$, which is just sufficient to inhibit the wild-type enzyme (ERG11) and stop growth.\n\nThe first mechanism is the overexpression of *CDR1* and *CDR2* efflux pumps. These pumps reduce drug accumulation by actively transporting fluconazole out of the cell. The effect of this mechanism is quantified by a fold-increase factor, $F_E$. This means that to achieve any given intracellular concentration $C_{in}$, a cell with overexpressed pumps requires an external concentration $F_E$ times greater than that required by a wild-type cell. For a cell with only this mechanism, the MIC, denoted $\\text{MIC}_E$, is the external concentration needed to reach the same critical intracellular concentration $C_{in,crit}$ at the still-wild-type target. Therefore, the relationship is:\n$$ \\text{MIC}_E = F_E \\times \\text{MIC}_{WT} $$\n\nThe second mechanism is a Y132F point mutation in the target enzyme, ERG11. This mutation reduces the binding affinity of fluconazole to the enzyme. Consequently, a higher intracellular drug concentration is needed to achieve the same degree of inhibition. This effect is quantified by a fold-increase factor, $F_T$. The new required critical intracellular concentration, $C_{in,crit,mut}$, is $F_T$ times higher than for the wild-type enzyme:\n$$ C_{in,crit,mut} = F_T \\times C_{in,crit} $$\nFor a cell with only this mutation (and wild-type efflux), the MIC, denoted $\\text{MIC}_T$, would be the external concentration needed to achieve this new, higher intracellular concentration. Thus:\n$$ \\text{MIC}_T = F_T \\times \\text{MIC}_{WT} $$\n\nNow, consider the clinical isolate possessing **both** mechanisms.\n- Due to the *ERG11* mutation, the required intracellular concentration for growth inhibition is elevated to $C_{in,crit,mut} = F_T \\times C_{in,crit}$.\n- Due to the overexpressed efflux pumps, achieving any target intracellular concentration requires an external concentration that is scaled up by the factor $F_E$.\n\nTo inhibit the growth of this dual-resistance isolate, the external drug concentration must be high enough to achieve the intracellular concentration $C_{in,crit,mut}$. The efflux pumps impose their multiplicative \"cost\" on achieving this concentration. The required external concentration, $\\text{MIC}_{combined}$, is therefore $F_E$ times the external concentration that would be needed if only the target mutation were present ($\\text{MIC}_T$).\n$$ \\text{MIC}_{combined} = F_E \\times \\text{MIC}_{T} $$\nSubstituting the expression for $\\text{MIC}_T$ from above:\n$$ \\text{MIC}_{combined} = F_E \\times (F_T \\times \\text{MIC}_{WT}) = (F_T \\times F_E) \\times \\text{MIC}_{WT} $$\nThe overall fold increase in MIC is the ratio $\\frac{\\text{MIC}_{combined}}{\\text{MIC}_{WT}}$, which is equal to the product of the individual fold increases, $F_T \\times F_E$. Because the mechanisms act on sequential and independent steps (drug entry/accumulation and target binding), their effects are **multiplicative**.\n\n**2. Calibration of Individual Effect Sizes**\n\nThe problem specifies using the sample-size-weighted geometric mean to calibrate the effect size for each mechanism. For a set of values $\\{x_1, x_2, \\dots, x_k\\}$ with corresponding weights (sample sizes) $\\{w_1, w_2, \\dots, w_k\\}$, the weighted geometric mean is calculated as:\n$$ \\text{GM}_{\\text{weighted}} = \\left( \\prod_{i=1}^{k} x_i^{w_i} \\right)^{1 / \\sum_{i=1}^{k} w_i} = \\exp\\left( \\frac{\\sum_{i=1}^{k} w_i \\ln(x_i)}{\\sum_{i=1}^{k} w_i} \\right) $$\n\n**For the *ERG11* Y132F mutation (Mechanism T):**\nData: $f_{T,1} = 8.0$ ($n_{T,1} = 30$), $f_{T,2} = 6.5$ ($n_{T,2} = 20$), and $f_{T,3} = 9.5$ ($n_{T,3} = 25$).\nTotal weight: $N_T = 30 + 20 + 25 = 75$.\nThe calibrated effect size, $F_T$, is:\n$$ F_T = \\exp\\left( \\frac{30 \\ln(8.0) + 20 \\ln(6.5) + 25 \\ln(9.5)}{75} \\right) $$\n$$ F_T \\approx \\exp\\left( \\frac{30(2.07944) + 20(1.87180) + 25(2.25129)}{75} \\right) $$\n$$ F_T \\approx \\exp\\left( \\frac{62.3832 + 37.4360 + 56.2823}{75} \\right) = \\exp\\left( \\frac{156.1015}{75} \\right) \\approx \\exp(2.081353) \\approx 8.01512 $$\n\n**For the *CDR1*/*CDR2* overexpression (Mechanism E):**\nData: $f_{E,1} = 3.0$ ($n_{E,1} = 40$), $f_{E,2} = 4.0$ ($n_{E,2} = 35$), and $f_{E,3} = 2.5$ ($n_{E,3} = 25$).\nTotal weight: $N_E = 40 + 35 + 25 = 100$.\nThe calibrated effect size, $F_E$, is:\n$$ F_E = \\exp\\left( \\frac{40 \\ln(3.0) + 35 \\ln(4.0) + 25 \\ln(2.5)}{100} \\right) $$\n$$ F_E \\approx \\exp\\left( \\frac{40(1.09861) + 35(1.38629) + 25(0.91629)}{100} \\right) $$\n$$ F_E \\approx \\exp\\left( \\frac{43.9444 + 48.5202 + 22.9073}{100} \\right) = \\exp\\left( \\frac{115.3719}{100} \\right) \\approx \\exp(1.153719) \\approx 3.17007 $$\n\n**3. Computation of the Overall Fold Increase**\n\nUsing the multiplicative model, the total predicted fold increase, $F_{total}$, is the product of the individual calibrated effects:\n$$ F_{total} = F_T \\times F_E $$\n$$ F_{total} \\approx 8.01512 \\times 3.17007 \\approx 25.4083 $$\nThe problem requires the final answer to be rounded to three significant figures.\n$$ F_{total} \\approx 25.4 $$", "answer": "$$\\boxed{25.4}$$", "id": "4616017"}]}